Key indicators: single-crystal X-ray study; T = 292 K; mean (C-C) = 0.005 Å; R factor = 0.066; wR factor = 0.203; data-to-parameter ratio = 13.0.
Related literature
For the preparation and biological activity of benzofuropyrimidine derivatives, see: Moneam et al. (2004) ; Bodke et al. (2003) . For -stacking interactions, see: Hu et al. (2005 Hu et al. ( , 2006 Hu et al. ( , 2007 Hu et al. ( , 2008 Janiak (2000) . For the structures of other fused pyrimidinone derivatives, see: Hu et al. (2005 Hu et al. ( , 2006 Hu et al. ( , 2007 Hu et al. ( , 2008 .
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). Data collection: SMART (Bruker, 2001 ); cell refinement: SAINTPlus (Bruker, 2001) ; data reduction: SAINT-Plus; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: PLATON (Spek, 2009) ; software used to prepare material for publication: SHELXTL (Sheldrick, 2008 (Moneam et al., 2004 and Bodke et al., 2003) . Some X-ray crystal structures of benzofuro[3,2-d]pyrimidinone derivatives have been reported (Hu et al., 2005 (Hu et al., , 2006 (Hu et al., , 2007 (Hu et al., , 2008 . The heterocyclic title compound (I) may be used as a new precursor for obtaining bioactive molecules and its structure is presented here (Fig.1 ).
In the molecule of (I), all ring atoms of benzofuro [2,3-d] 
For background references, see: Hu et al. (2008) .
Refinement
All H atoms were located in difference maps and treated as riding atoms with C-H = 0.93 Å, U iso =1.2U eq (C) for Csp 2 , C-H = 0.97 Å, U iso = 1.2U eq (C) for CH 2 , O-H = 0.82 Å, U iso = 1.2U eq (C) for OH, N-H = 0.86 Å, U iso = 1.2U eq (N) for NH. Figures   Fig. 1 . View of the molecular structure of the title compound, showing the atom labelling scheme and with displacement ellipsoids drawn at 50% probability level. [Symmetry code: (a) -x, y, -z +3/2]. 
